DOCSLIB.ORG

Attentional Bias to Itch-Related Images in a Clinical Itch Population

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Attentional Bias to Itch-Related Images in a Clinical Itch Population This is a repository copy of Attentional bias to itch-related images in a clinical itch population. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/139903/ Version: Published Version Proceedings Paper: Young, M, Burke, M and Lloyd, D orcid.org/0000-0003-3589-7383 (2017) Attentional bias to itch-related images in a clinical itch population. In: Acta Dermato-Venereologica. 9th World Congress on Itch, 15-17 Oct 2017, Wroclaw, Poland. Society for Publication of Acta Dermato-Venereologica , p. 1009. Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative works on the same terms. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ ISSN 0001-5555 ActaDV Volume 97 2017 SEPTEMBER, No. 8 ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Abstracts from the 9th World Congress on Itch October 15–17, 2017 Official Journal of - European Society for Dermatology and Wroclaw, Poland Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv Abstracts from the 9th World Congress on Itch DV cta A enereologica V Organizing Committee Scientiic Committee ermato- Congress President: Jacek C Szepietowski (Wroclaw, Poland) Jeffrey D. Bernhard (Massachusetts, USA) D Congress Secretary General: Adam Reich (Rzeszów, Poland) Earl Carstens (Davis, USA) Congress Secretary: Edyta Lelonek (Wroclaw, Poland) Toshiya Ebata (Tokyo, Japan) cta Alan Fleischer (Lexington, USA) A IFSI President: Earl Carstens (Davis, USA) IFSI Vice President: Elke Weisshaar (Heidelberg, Germany) Ichiro Katayama (Osaka, Japan) Ethan Lerner (Boston, USA) Staff members of the Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland Thomas Mettang (Wiesbaden, Germany) Martin Schmelz (Mannheim, Germany) Sonja Ständer (Münster, Germany) DV Jacek C. Szepietowski (Wroclaw, Poland) cta Kenji Takamori (Tokyo, Japan) A Elke Weisshaar (Heidelberg, Germany) Gil Yosipovitch (Miami, USA) Contents of this Abstract book Program 1000 Abstracts: Lecture Abstracts 1008 Poster Abstracts 1035 Author Index 1059 dvances in dermatology and venereology in dermatology and dvances A www.medicaljournals.se/acta doi: 10.2340/00015555-2773 Journal Compilation © 2017 Acta Dermato-Venereologica. Acta Derm Venereol 2017; 97: 999–1060 1000 9th World Congress of Itch Sunday, October 15, 2017 Abstract # 1:30-3:30 PM IFSI Board meeting DV 5:00-5:20 PM OPENING CEREMONY 5:00-5:10 PM Opening remarks cta Jacek C. Szepietowski (Poland) A 5:10-5:20 PM Opening remarks IFSI: A successful society for the future Earl Carstens (USA) 5:20-7:00 PM Plenary Session Chairs: Earl Carstens (USA); Elke Weisshaar (Germany) 5:20-5:50 PM Bernhard Lecture OP1 Itchy dermatoses in the collection of Wroclaw moulages Jacek C. Szepietowski (Poland) 5:50-6:20 PM Kuraishi Lecture OP2 enereologica Speciicity or pattern: implications for clinical itch V Martin Schmelz (Germany) 6:20-6:50 PM Neisser Lecture OP3 Itch and psyche Mohammad Jafferany (USA) ermato- D cta A Monday, October 16, 2017 AM 8:30-9:00 AM Morning session Hot off the bench: Latest news by young investigators Chairs: Hermann Handwerker (Germany); Adam Reich (Poland) DV 8:30-8:40 AM The regulation of pruritus in psoriasis and atopic dermatitis – a possible role for CD26/DPPIV OP4 Eriko Komiya-Suyama (Japan), Ryo Hatano, Haruna Otsuka, Takumi Itoh, Hiroto Yamazaki, cta Yasushi Suga, Utako Kimura, Taketo Yamada, Mitsutoshi Tominaga, Kenji Takamori, Kei Ohnuma, Chikao Morimoto A 8:40-8:50 AM Chronic itch in hemodialysis patients: A follow-up study of GEHIS (German Epidemiological OP5 Hemodialysis-Itch Study) Natalie Plewig (Germany), Robert Ofenloch, Thomas Mettang, Elke Weisshaar 8:50-9:00 AM Attentional bias to itch-related images in a clinical itch population OP6 Michellie Young (UK), Melanie Burke, Donna Lloyd 9:05-10:30 AM Plenary Session Neurobiology of Itch Chairs: Martin Steinhoff (Ireland); Matthias Ringkamp (USA); 9:05-09:25 AM Effects of pruritogens and algogens on rostral ventromedial medullary (RVM) ON and OFF OP7 cells T. Follansbee, Iodi Carstens (USA), Earl Carstens, T. Akiyama, M. Fujii, A. Davoodi, M. Nagamine 9:25-09:45 AM How scratching can take its “Toll” on itch, new insights into innate immune mechanisms of OP8 peripheral itch sensitisation Ian McDonald (Ireland), Attila Szöllsi, Imre Szabó Lrinc, Martin Steinhoff 9:45-10:00 AM Preferential activation of subtypes of polymodal nociceptive C-ibers in pigtail monkey OP9 following intradermal injection of -alanine and bovine medullary protein 8-22 Amanda H Klein, Timothy V Hartke, Matthew Wooten, Gang Wu, Matthias Ringkamp (USA) 10:00-10:15 AM Itch as a basic constituent of somatosensation: Evidence for multi-modal capacity of primary OP10 C-afferents Behrang Sharif (Canada), Ariel Ase, Alfredo Ribeiro da Silva, Philippe Séguéla 10:15-10:30 AM Sulfated CCK8 induces alloknesis via spinal CCK2 receptor in mice OP11 Mitsutoshi Tominaga (Japan), Fumiya Kusube, Kotaro Honda, Nobuaki Takahashi, Hisashi dvances in dermatology and venereology in dermatology and dvances Naito, Fumiyuki Yamakura, Yasushi Suga, Yasuhiro Tomooka, Kenji Takamori A www.medicaljournals.se/acta Program 1001 11:00 AM-12:30 Concurrent I PM Special Interest Groups (SIGs) Chairs: Thomas Mettang (Germany); Jacek C. Szepietowski (Poland) DV 11:00-11:15 AM SIG Sensitive Skin OP12 Laurent Misery (France), Sonja Ständer, Jacek C. Szepietowski, Adam Reich, Joanna cta Wallengren, Andrea W.M. Evers, Kenji Takamori, Emilie Brenaut, Christelle Le Gal-Ianotto, A Joachim Fluhr, Enzo Berardesca, Elke Weisshaar 11:15-11:30 AM SIG Scoring itch in clinical trials OP13 Sonja Ständer (Germany), Matthias Augustin, Jacek C. Szepietowski 11:30-11:45 AM SIG Questionnaires OP14 Elke Weisshaar (Germany), Jörg Kupfer, Antoinette van Laarhoven, Uwe Gieler, Masutaka Furue, Hidehisa Saeki, Andrea Evers, Gil Yosipovitch 11:45 AM-12:00 SIG Paraneoplastic itch OP15 PM Elke Weisshaar (Germany), Thomas Mettang, Sonja Ständer, Frank Brennan, Hong Liang Tey, Gil Yosipovitch enereologica 12:00-12:15 PM SIG Uremic itch OP16 V Thomas Mettang (Germany), Jacek C. Szepietowski, Laurent Misery, Elke Weisshaar 12:15-12:30 PM Discussion 11:00 AM-12:30 Concurrent II ermato- PM Skin, inlammation and itch D Chairs: Brian Kim (USA); Laurent Misery (France) 11:00-11:15 AM New insights into the pathophysiology of itch during ciguatera ish poisoning OP17 cta Killian L’Herondelle (France), Laurent Misery, Christelle Le Gall-Ianotto, Réginald Philippe, A Matthieu Talagas, Olivier Mignen, Richard Lewis, Raphaele Le Garrec 11:15-11:30 AM Intra- and extra-lesional sensitization for non-histaminergic and mechanically-evoked itch in OP18 atopic dermatitis Hjalte Holm Andersen (Denmark), Jesper Elberling, Henrik Sølvsten, Gil Yosipovitch, Lars Arendt-Nielsen DV 11:30-11:45 AM Attenuated activation of endogenous glucocorticoids in keratinocytes induces alloknesis in OP19 atopic dermatitis via aberrant artemin production cta Akira Matsumoto (Japan), Hiroyuki Murota, Mika Terao, Ichiro Katayama 11:45 AM-12:00 Neutrophil-somatosensory neuron crosstalk drives acute and chronic itch OP20 A PM Carolyn Walsh (USA), Jamie Schwendinger-Schreck, Jacques Deguine, Emily Brock, Rose Hill, Jessica Wei, Natalie Kelava Kucirek, Karsten Gronert, Greg Barton, Diana Bautista 12:00-12:15 PM Cutaneous 4-1BB/4-1BBL signaling induces severe skin inlammation and chronic itch OP21 Stefan Tran, Verena Kupas, Kristian Holz, Marcus Maurer, Thomas A. Luger, Sonja Ständer, Karin Loser (Germany) 12:15-12:30 PM Sema3A expression is regulated by calcium/PKC/MAPK/AP-1 signaling axis in normal human OP22 epidermal keratinocytes Yayoi Kamata (Japan), Yoshie Umehara, Azumi Sakaguchi, Yasushi Suga, Mitsutoshi Tominaga, Kenji Takamori 12:30-2:00 PM Lunch and poster viewing I Chairs: Elke Weisshaar (Germany), Gil Yosipovitch (USA) 2:00-3:30 PM Plenary session New antipruritic treatments Chairs: Sonja Ständer (Germany); Alan Fleischer (USA) 2:00-2:15 PM Randomized, double-blind, placebo-controlled phase 2 clinical trial of serlopitant effects on OP23 multiple measures of pruritus in patients with prurigo nodularis Sonja Ständer (Germany), Paul Kwon, Thomas A. Luger 2:15-2:30 PM Serlopitant for treatment of chronic pruritus: results of a randomized, multicenter, double- OP24 blind, placebo-controlled phase 2 clinical trial Gil Yospovitch (USA), Sonja Ständer, Matthew B. Kerby, James W. Larrick, Andrew J. Perlman, Edward F. Schnipper, Xiaoming Zhang, Jean Y. Tang, Thomas A. Luger, Martin Steinhoff 2:30-2:45 PM Recovery of peptidergic epidermal nerve iber density by Tofacitinib in a mouse model of OP25 dvances in dermatology and venereology in dermatology and dvances atopic dermatitis A Kristen Sanders (USA), Kento Sakai, Gil Yosipovitch, Tasuku Akiyama Acta Derm Venereol 2017 1002 9th World
Load more

Recommended publications
  • ( 12 ) United States Patent
    US009974742B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 974 , 742 B2 Ottoboni et al. (45 ) Date of Patent: * May 22, 2018 ( 54 ) EMULSION FORMULATIONS OF AN NK - 1 2013 /0236501 A1 * 9 /2013 Booth . .. .. .. A61K 9 /0019 424 / 400 RECEPTOR ANTAGONIST AND USES 2013 /0317016 AL 11 /2013 Hingorani et al. THEREOF 2016 / 0024092 Al 1 / 2016 Wan et al. 2016 / 0082013 Al 3 / 2016 Ottoboni et al . @(71 ) Applicant : Heron Therapeutics , Inc. , Redwood 2016 /0206622 A1 3 / 2016 Ottoboni et al . City , CA (US ) 2017 / 0112847 AL 4 /2017 Ottoboni et al. @(72 ) Inventors : Thomas B . Ottoboni, Belmont, CA (US ) ; Han Han , Mountain View , CA FOREIGN PATENT DOCUMENTS (US ) CN 102379 * 3 / 2012 CN 102379845 A 3 / 2012 @(73 ) Assignee : Heron Therapeutics, Inc. , San Diego , WO WO 2005 /016308 AL 2 / 2005 WO WO 2009 / 124756 AL 10 / 2009 CA (US ) WO WO 2011 / 158053 AL 12 / 2011 WO WO 2013 / 177501 A2 11 / 2013 @( * ) Notice : Subject to any disclaimer , the term of this WO WO 2014 /0209962 AL 12 /2014 patent is extended or adjusted under 35 WO WO 2014 /005606 AL 3 / 2016 U . S . C . 154 ( b ) by 0 days . days . WO WO 2016 /044784 Al 3 / 2016 This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS (21 ) Appl. No. : 15 /012 , 532 Cassileth et al. in Arch . Intern Med . 1983 ; 143 ( 7 ) : 1347 - 1349 ( Abstract ) . * Dexamethasone Hydrogen Phosphate at web .archive . org/ web / ( 22 ) Filed : Feb . 1 , 2016 20141224130045 /http :/ /www . drugs . com / pro / dexamethasone -so dium -phosphate .html ( retrieved on the internet Mar.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0038462 A1 ZHANG Et Al
    US 20160038462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0038462 A1 ZHANG et al. (43) Pub. Date: Feb. 11, 2016 (54) USE OF NK-1 RECEPTOR ANTAGONISTS IN (60) Provisional application No. 61/838,784, filed on Jun. PRURTUS 24, 2013. (71) Applicant: TIGERCAT PHARMA, INC., South Publication Classification San Francisco, CA (US) (51) Int. Cl. (72) Inventors: Xiaoming ZHANG, Sunnyvale, CA A613 L/403 (2006.01) (US); Edward F. SCHNIPPER, A6II 45/06 (2006.01) Redwood City, CA (US); Andrew J. A619/00 (2006.01) PERLMAN, Stanford, CA (US); James (52) U.S. Cl. W. LARRICK, Sunnyvale, CA (US) CPC ............. A6 IK3I/403 (2013.01); A61 K9/0053 (2013.01); A61 K9/0014 (2013.01); A61 K (21) Appl. No.: 14/922,684 45/06 (2013.01) (57) ABSTRACT (22)22) Filed: Oct. 26,9 2015 The invention relates to methods for treatingg pruritusp with NK-1 receptor antagonists such as serlopitant. The invention O O further relates to pharmaceutical compositions comprising Related U.S. Application Data NK-1 receptorantagonists such as serlopitant. In addition, the (60) Division of application No. 14/312.942, filed on Jun. invention encompasses treatment of a pruritus-associated 24, 2014, now Pat. No. 9,198.898, which is a continu condition with serlopitant and an additional antipruritic ation-in-part of application No. 13/925,509, filed on agent, and the use of serlopitant as a sleep aid, optionally in Jun. 24, 2013, now Pat. No. 8,906,951. combination with an additional sleep-aiding agent. Patent Application Publication Feb.
    [Show full text]
  • Neurokinin Receptor NK Receptor
    Neurokinin Receptor NK receptor There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues. www.MedChemExpress.com 1 Neurokinin Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators Aprepitant Befetupitant (MK-0869; MK-869; L-754030) Cat. No.: HY-10052 (Ro67-5930) Cat. No.: HY-19670 Aprepitant (MK-0869) is a selective and Befetupitant is a high-affinity, nonpeptide, high-affinity neurokinin 1 receptor antagonist competitive tachykinin 1 receptor (NK1R) with a Kd of 86 pM. antagonist. Purity: 99.67% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg Biotin-Substance P Casopitant mesylate Cat. No.: HY-P2546 (GW679769B) Cat. No.: HY-14405A Biotin-Substance P is the biotin tagged Substance Casopitant mesylate (GW679769B) is a potent, P. Substance P (Neurokinin P) is a neuropeptide, selective, brain permeable and orally active acting as a neurotransmitter and as a neurokinin 1 (NK1) receptor antagonist.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • The Neurokinin-1 Receptor Is Expressed with Gastrin-Releasing
    Research Articles: Cellular/Molecular The neurokinin-1 receptor is expressed with gastrin-releasing peptide receptor in spinal interneurons and modulates itch https://doi.org/10.1523/JNEUROSCI.1832-20.2020 Cite as: J. Neurosci 2020; 10.1523/JNEUROSCI.1832-20.2020 Received: 15 July 2020 Revised: 25 August 2020 Accepted: 21 September 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 the authors 1 Title: The neurokinin-1 receptor is expressed with gastrin-releasing peptide receptor in spinal 2 interneurons and modulates itch 3 4 Abbreviated Title: Neurokinin-1 receptor spinal neurons mediate itch 5 6 7 Authors: Tayler D. Sheahan1, Charles A. Warwick1, Louis G. Fanien1, Sarah E. Ross1 8 9 10 1Pittsburgh Center for Pain Research and Department of Neurobiology, University of Pittsburgh, 11 Pennsylvania 12 13 Corresponding author: Sarah E. Ross, Department of Neurobiology, University of Pittsburgh, 14 200 Lothrop Street, Pittsburgh, PA, e-mail: [email protected] 15 The authors have no conflicts of interest to declare. 16 17 18 Number of text pages: 19 19 20 21 Number of figures and tables: 5 figures 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 1 50 Abstract 51 52 The neurokinin-1 receptor (NK1R, encoded by Tacr1) is expressed in spinal dorsal horn 53 neurons and has been suggested to mediate itch in rodents.
    [Show full text]
  • Neurokinin-1 Antagonist Orvepitant for EGFRI- Induced
    Open access Original research BMJ Open: first published as 10.1136/bmjopen-2019-030114 on 6 February 2020. Downloaded from Neurokinin-1 antagonist orvepitant for EGFRI- induced pruritus in patients with cancer: a randomised, placebo- controlled phase II trial Bruno Vincenzi ,1 Mike Trower ,2 Ajay Duggal ,3 Pamela Guglielmini ,4 Peter Harris ,2 David Jackson ,5 Mario E Lacouture ,6 Emiliangelo Ratti ,2 Giuseppe Tonini ,1 Andrew Wood ,7 Sonja Ständer 8 To cite: Vincenzi B, Trower M, ABSTRACT Strengths and limitations of this study Duggal A, et al. Neurokinin-1 Objective To evaluate the efficacy of orvepitant (10 or antagonist orvepitant for 30 mg given once daily, orally for 4 weeks), a neurokinin-1 EGFRI- induced pruritus ► The RELIEVE 1 study was the first randomised, in patients with cancer: a receptor antagonist, compared with placebo in reducing double- blind, placebo- controlled study of a neuroki- randomised, placebo- controlled the intensity of epidermal growth factor receptor inhibitor nin-1 antagonist for epidermal growth factor recep- phase II trial. BMJ Open (EGFRI)- induced intense pruritus. tor inhibitor- induced pruritus. 2020;10:e030114. doi:10.1136/ Design Randomised, double- blind, placebo- controlled ► Patients reported scores for the primary endpoint of bmjopen-2019-030114 clinical trial. reduction of itch intensity on a daily basis using an ► Prepublication history for Setting 15 hospitals in Italy and five hospitals in the UK. interactive voice response system. this paper is available online. Participants 44 patients aged ≥18 years receiving an ► Effects on sleep and quality of life were also To view these files, please visit EGFRI for a histologically confirmed malignant solid tumour measured.
    [Show full text]
  • WO 2018/005695 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2018/005695 A l 0 4 January 2018 (04.01.2018) W ! P O PCT (51) International Patent Classification: (72) Inventors: BASTA, Steven; 590 Berkeley Avenue, Menlo A61K 31/4035 (2006.01) A61P 17/04 (2006.01) Park, CA 94025 (US). JOING, Mark; 936 Clara Drive, Pa A61K 45/06 (2006.01) lo Alto, CA 94303 (US). ZHANG, Xiaoming; 1089 Rem- sen Court, Sunnyvale, CA 94087 (US). KWON, Paul; 3349 (21) International Application Number: Deer Hollow Dr, Danville, CA 94506 (US). PCT/US20 17/039829 (74) Agent: SILVERMAN, Lisa, N.; Morrison & Foerster LLP, (22) International Filing Date: 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). 28 June 2017 (28.06.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/356,280 29 June 2016 (29.06.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/356,291 29 June 2016 (29.06.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/356,301 29 June 2016 (29.06.2016) us MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/356,294 29 June 2016 (29.06.2016) us OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/356,286 29 June 2016 (29.06.2016) us SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, 62/356,271 29 June 2016 (29.06.2016) us TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Inmunolocalización De La Sustancia Py Del Receptor
    UNIVERSIDAD DE SEVILLA FACULTAD DE MEDICINA DEPARTAMENTO DE CIRUGÍA TESIS DOCTORAL INMUNOLOCALIZACIÓN DE LA SUSTANCIA P Y DEL RECEPTOR NK1 EN LAS ESTRUCTURAS DEL SISTEMA NERVIOSO CENTRAL IMPLICADAS EN LA ENFERMEDAD DE ALZHEIMER-KRAEPELIN Amparo Murciano Rosado Sevilla 2015 Agradecimientos Mi más profundo agradecimiento a mis directores de tesis. Al Dr. D. Miguel Muñoz Sáezpor su amor por el conocimiento, su necesidad de transmitir su saber y entusiasmo a todoel que esté dispuesto a recibirlo. A la Dra. Dña. Inmaculada Bueno Rodríguez por su dedicación, paciencia y disponibilidad. Por su Amistad desde la infancia y por liarme en este mundo de la investigación. A mi bisabuelo Ramón, mi abuelo Gabriel, mi tía Carmen y mi tío y padrino Ramón, a mis hermanos Antonio y Montserrat y a mi sobrina Mª Paz, tronco y sabia antigua y nueva del amor por la medicina familiar. A todos mis compañeros y amigos que me han facilitado la realización de este trabajo. A Dña Ana Moreno, responsable de Doctorado de la Universidad de Sevilla, por sus consejos y orientación que han sido claves. A Dña Isabel Mª Rodríguez del Nodo coordinador del Biobanco del SSPA, Dña Carolina Castilla, del Nodo de Biobanco de Sevilla y a Dña Carmen Pérez del Nodo de Biobanco de Córdoba, por su interés y disponibilidad en la gestión de las muestras. A D. Andrés Carranza, Patólogo de Hospital UniversaitaioVirgen del Rocío y DñaMaría García Martos, Patóloga del Hospital Universitario del Sureste de Madrid, por su disponibilidad y colaboración en el proceso de inmunohistoquímica. A mi padre, por los consejos y por el amor que me han brindado siempre, por ser un ejemplo de generosidad, trabajo, honradez y por estar ahí.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0231688 A1
    US 20190231688A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0231688 A1 Ottoboni et al. (43 ) Pub. Date : Aug. 1 , 2019 ( 54 ) METHOD OF ADMINISTERING EMULSION A61K 9 / 00 ( 2006 .01 ) FORMULATIONS OF AN NK - 1 RECEPTOR A61K 47 / 24 (2006 .01 ) ANTAGONIST A61K 31/ 573 (2006 . 01 ) A61K 47 /44 ( 2006 .01 ) (71 ) Applicant: Heron Therapeutics , Inc . , San Diego , A61K 47/ 10 ( 2006 .01 ) CA (US ) A61K 47 / 12 ( 2006 . 01 ) A61K 47 / 26 ( 2006 . 01 ) ( 72 ) Inventors : Thomas B . Ottoboni, Belmont, CA A61K 31/ 496 ( 2006 .01 ) ( US ) ; Barry D . Quart, Las Vegas, NV (52 ) U . S . CI. (US ) CPC .. .. .. A61K 9 / 107 ( 2013 . 01 ) ; A61K 31/ 5377 ( 2013 .01 ) ; A61K 9 /0019 ( 2013 . 01 ) ; A61K ( 21 ) Appl. No .: 16 / 261, 459 47 / 24 ( 2013 .01 ) ; A61K 31 /496 ( 2013 .01 ) ; A61K 47/ 44 ( 2013 .01 ) ; A61K 47 /10 (2013 .01 ) ; (22 ) Filed : Jan . 29 , 2019 A61K 47 /12 ( 2013 .01 ) ; A61K 47 /26 ( 2013 .01 ) ; Related U . S . Application Data A61K 31/ 573 (2013 .01 ) ( 60 ) Provisional application No . 62/ 624 , 050 , filed on Jan . 30 , 2018 . (57 ) ABSTRACT Publication Classification ( 51 ) Int. Ci. Disclosed herein are methods of administering pharmaceu A61K 9 / 107 ( 2006 .01 ) tical formulations of a neurokinin - 1 (NK - 1 ) receptor antago A61K 31/ 5377 ( 2006 . 01 ) nist to a subject in need of treatment of emesis . Patent Application Publication Aug. 1 , 2019 Sheet 1 of 4 US 2019/ 0231688 A1 Ayyyyy . * L-9.21um SSS * 44 FIG.1B FIG.1D . S MXXS .91umL-2 FIG.1A FIG.1C * : * :: : : 00 28 PO20.
    [Show full text]
  • Neurokinin Receptor NK Receptor
    Neurokinin Receptor NK receptor There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues. www.MedChemExpress.com 1 Neurokinin Receptor Inhibitors & Modulators Aprepitant Befetupitant (MK-0869; MK-869; L-754030) Cat. No.: HY-10052 (Ro67-5930) Cat. No.: HY-19670 Bioactivity: Aprepitant (MK-0869) is a selective and high-affinity Bioactivity: Befetupitant is a high-affinity, nonpeptide, competitive neurokinin 1 receptor antagonist with a Kd of 86 pM. tachykinin 1 receptor ( NK1R) antagonist. Purity: 99.93% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 1 mg, 5 mg, 10 mg, 20 mg 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg Fezolinetant Fosaprepitant (ESN-364) Cat. No.: HY-19632 (L-758298) Cat. No.: HY-14407 Bioactivity: Fezolinetant is an antagonist of the neurokinin 3 receptor Bioactivity: Fosaprepitant (L-758298) is a neurokinin-1 receptor antagonist (NK3R), used for the treatment of menopausal hot flushes.
    [Show full text]